Agenus (AGEN) News Today $6.56 +0.59 (+9.88%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 4:21 PM | finance.yahoo.comThe Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin PharmaceuticalJuly 26 at 4:21 PM | finance.yahoo.comAgenus to Provide Second Quarter 2024 Financial Report and Corporate UpdateJuly 26 at 2:31 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGENJuly 24 at 2:35 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGENJuly 22, 2024 | prnewswire.comAGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law FirmJuly 22, 2024 | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Receives $31.00 Consensus Target Price from BrokeragesJuly 21, 2024 | msn.comJefferies Downgrades Agenus (AGEN)July 21, 2024 | americanbankingnews.comJefferies Financial Group Reiterates Hold Rating for Agenus (NASDAQ:AGEN)July 21, 2024 | americanbankingnews.comAgenus (NASDAQ:AGEN) Cut to "Neutral" at HC WainwrightJuly 20, 2024 | markets.businessinsider.comHold Rating Justified for Agenus Amidst Regulatory Uncertainties and Mixed Clinical ResultsJuly 20, 2024 | msn.comAgenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapyJuly 20, 2024 | americanbankingnews.comAgenus (NASDAQ:AGEN) Downgraded to Hold at Baird R WJuly 19, 2024 | finanznachrichten.deAgenus Inc.: Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerJuly 19, 2024 | marketwatch.comAgenus Shares Sink After FDA Discourages Accelerated ApprovalJuly 19, 2024 | finance.yahoo.comAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerJuly 19, 2024 | markets.businessinsider.comNavigating Uncertainty: Hold Rating on Agenus Amidst FDA Hurdles and Efficacy QuestionsJuly 19, 2024 | msn.comAgenus stock plunges 60% on FDA feedback on BOT/BAL therapyJuly 19, 2024 | markets.businessinsider.comAgenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial ClarityJuly 19, 2024 | marketbeat.comAgenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by BrokeragesShares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have been assigned an average recommendation of "Hold" from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and one has issued aJuly 19, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Earns "Hold" Rating from Jefferies Financial GroupJefferies Financial Group reissued a "hold" rating and set a $7.00 price objective (up previously from $3.00) on shares of Agenus in a report on Friday.July 19, 2024 | globenewswire.com$6.6 Bn Herpes Simplex Virus Infections Markets - Global Strategic Business Report to 2030 with Coverage of 10+ Major Players Including Admedus, Agenus, and Aicuris Anti-infective CuresJuly 19, 2024 | americanbankingnews.comAgenus (NASDAQ:AGEN) Downgraded by William BlairJuly 19, 2024 | americanbankingnews.comRobert W. Baird Downgrades Agenus (NASDAQ:AGEN) to NeutralJuly 19, 2024 | marketbeat.comRobert W. Baird Lowers Agenus (NASDAQ:AGEN) to NeutralRobert W. Baird lowered shares of Agenus from an "outperform" rating to a "neutral" rating and cut their price objective for the company from $35.00 to $8.00 in a report on Friday.July 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGENJuly 18, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Downgraded by William Blair to "Market Perform"William Blair lowered shares of Agenus from an "outperform" rating to a "market perform" rating in a report on Thursday.July 18, 2024 | investorplace.comWhy Is Agenus (AGEN) Stock Down 55% Today?July 18, 2024 | americanbankingnews.comAgenus Inc. (NASDAQ:AGEN) Sees Significant Growth in Short InterestJuly 17, 2024 | marketbeat.comAgenus Inc. (NASDAQ:AGEN) Short Interest UpdateAgenus Inc. (NASDAQ:AGEN - Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 2,360,000 shares, an increase of 5.4% from the June 15th total of 2,240,000 shares. Based on an average trading volume of 823,500 shares, the short-interest ratio is presently 2.9 days. Currently, 11.8% of the shares of the company are sold short.July 13, 2024 | marketbeat.comGSA Capital Partners LLP Reduces Stake in Agenus Inc. (NASDAQ:AGEN)GSA Capital Partners LLP reduced its position in Agenus Inc. (NASDAQ:AGEN - Free Report) by 47.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,271,004 shares of the biotechnology company's stock afteJuly 9, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Stock Passes Above 200 Day Moving Average of $12.94Agenus (NASDAQ:AGEN) Stock Price Crosses Above 200-Day Moving Average of $12.94June 30, 2024 | marketbeat.comShort Interest in Agenus Inc. (NASDAQ:AGEN) Drops By 17.9%Agenus Inc. (NASDAQ:AGEN - Get Free Report) saw a significant drop in short interest in June. As of June 15th, there was short interest totalling 2,240,000 shares, a drop of 17.9% from the May 31st total of 2,730,000 shares. Approximately 11.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 803,700 shares, the short-interest ratio is presently 2.8 days.June 28, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Agenus (NASDAQ:AGEN)HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Agenus in a research note on Friday.June 28, 2024 | businesswire.comSignificant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI ConferenceJune 17, 2024 | businesswire.comAgenus Announces Appointment of Dr. Jennifer Buell to Its Board of DirectorsJune 13, 2024 | businesswire.comNature Medicine Reports Agenus' Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50June 11, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average of $12.95Agenus (NASDAQ:AGEN) Stock Passes Above Two Hundred Day Moving Average of $12.95June 4, 2024 | businesswire.comAgenus Announces Virtual Annual Shareholders MeetingJune 1, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Stock Passes Above 200-Day Moving Average of $12.85Agenus (NASDAQ:AGEN) Stock Passes Above 200 Day Moving Average of $12.85May 30, 2024 | investorplace.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 29, 2024 | seekingalpha.comAgenus: Multiple Milestones In The Second Half Of 2024May 27, 2024 | investorplace.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study ResultsMay 24, 2024 | businesswire.comAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | marketbeat.comAgenus (NASDAQ:AGEN) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Agenus in a report on Friday.May 23, 2024 | businesswire.comBreakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual MeetingMay 23, 2024 | businesswire.comAgenus to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceMay 22, 2024 | fool.com3 Magnificent Growth Stocks to Buy Hand Over FistMay 18, 2024 | uk.investing.comAgenus sets FDA meeting for cancer therapy pathMay 16, 2024 | finance.yahoo.comFDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Get out of cash before the Fed's next meeting (Ad)"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview AGEN Media Mentions By Week AGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGEN News Sentiment▼-0.080.61▲Average Medical News Sentiment AGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGEN Articles This Week▼203▲AGEN Articles Average Week Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Athira Pharma News Precision BioSciences News Aligos Therapeutics News Adaptimmune Therapeutics News Sutro Biopharma News Poseida Therapeutics News Lexicon Pharmaceuticals News Vanda Pharmaceuticals News XOMA News Codexis News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGEN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
